 SEATTLE, Nov. 10, 2020 GLOBE NEWSWIRE -- Adaptive Biotechnologies Corporation Nasdaq: ADPT, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a collaboration with GlaxoSmithKline plc GSK to use its clonoSEQ Assay to assess minimal residual disease MRD in GSKs portfolio of hematology products. 